Qiagen N.V. Market Share Analysis

Find Industry reports, Company profiles
ReportLinker and Market Statistics

>> Get this Report Now by email!

Qiagen N.V. Market Share Analysis
Published on September 2010

Report Summary


Summary

GlobalData's new report, 'Qiagen N.V. Market Share Analysis' provides in-depth information on Qiagen's market position in the
different medical equipment markets it operates in. The report provides Qiagen's market share information in two key market
categories ' Genetic Testing and Infectious Immunology. The report also provides data and information on the overall competitive
landscape of the markets, the company operates in. The report is supplemented with global corporate-level profile with information on
the company's business segments, major products and services, competitors, locations and subsidiaries, financial deals and other
key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house
analysis by GlobalData's team of industry experts.

Scope

- Global company shares (in Revenues) information for the key markets Qiagen operates in ' In Vitro Diagnostics.
- Qiagen's company shares (in Revenues) information for all the key countries the company has presence in ' United States, Canada,
UK, Germany, France, Italy, Spain, Japan, China, India, and Australia.
- Qiagen's company shares (in Revenues) information for all the key market categories the company has presence in ' Genetic
Testing and Infectious Immunology.
- All the key data-points are for 2009 and cover all the key regions ' North America, Europe, Asia Pacific (APAC), and Middle East and
Africa (MEA).
- Global corporate-level profile with information on the company's business segments, major products and services, competitors, and
locations and subsidiaries.
- The company profile is also supplemented with a SWOT Analysis with in-depth information and analysis of the company's value
proposition and the business climate it operates in.
- Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any ' Mergers & Acquisitions
(M&A), Asset Transactions, PE/VC, Equity Offerings, Debt Offerings, and Partnerships.

Reasons to buy

- Develop sales and marketing strategies by identifying who-stands-where in the markets, Qiagen operates in.
- Plan your competition strategies by identifying the company's shares in the markets and geographic regions it operates in.
- Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are
involved in.
- Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in
the report.
- Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not
limited to Qiagen's market positions.

Qiagen N.V. Market Share Analysis Page 1/11


Table of Content

1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
2.1 What Is This Report About' 13
3 Definitions of Markets/Categories Covered 14
3.1 In Vitro Diagnostics 14
3.1.1 Clinical Chemistry 14
3.1.2 Genetic Testing 14
3.1.3 Haematology 14
3.1.4 Histology And Cytology 14
3.1.5 Immuno Chemistry 14
3.1.6 Infectious Immunology 14
3.1.7 Microbiology Culture 14
4 Company Snapshot 15
4.1 Key Information 15
4.2 Company Overview 15
4.3 Financial Performance 15
4.4 SWOT Snapshot 15
4.5 Business Overview 16
4.6 Major Products and Services 17
4.6.1 Overview 17
5 History 20
6 SWOT Analysis 23
6.1 Overview 23
6.2 Qiagen N.V. Strengths 23
6.2.1 Strong Research and Development Activities 23
6.2.2 Wide Geographical Presence 24
6.2.3 Broad Product Portfolio 24
6.2.4 Strong Financial Performance 24
6.3 Qiagen N.V. Weaknesses 24
6.3.1 Long Term Debts 24
6.3.2 Pending Litigations 25
6.4 Qiagen N.V. Opportunities 25
6.4.1 Biotech Focus 25
6.4.2 Potential Market 25
6.4.3 Market Growth in Emerging Economies 25
6.4.4 Inorganic Growth Strategy 26
6.4.5 New Product Launches 26
6.5 Qiagen N.V. Threats 26
6.5.1 Stringent Government Regulations 26
6.5.2 Competitive Landscape 26
6.5.3 Rapid Technological Change 27
6.5.4 Cost Containment Pressures 27



7 Competitors 28
8 Competitive Landscape 29
8.1 In Vitro Diagnostics, Global, Company Share (%), 2009 29
9 Qiagen N.V. Medical Equipment Market Share Analysis 31
9.1 Qiagen N.V., In Vitro Diagnostics, Global, Market Share (2009) 31
9.2 Qiagen N.V., Asia-Pacific, Market Share (2009) 32
9.3 Qiagen N.V., Europe, Market Share (2009) 33
9.4 Qiagen N.V., Middle East and Africa, Market Share (2009) 34
9.5 Qiagen N.V., North America, Market Share (2009) 35
9.6 Qiagen N.V., South and Central America, Market Share (2009) 36
10 Qiagen N.V. Medical Equipment Market Share Analysis by Category 37
10.1 Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (2009) 37
10.2 Qiagen N.V., Asia-Pacific, Category Revenue Share (2009) 39
10.2.1 Qiagen N.V., Australia, Category Revenue Share (2009) 41
10.2.2 Qiagen N.V., China, Category Revenue Share (2009) 43
10.2.3 Qiagen N.V., India, Category Revenue Share (2009) 45
10.2.4 Qiagen N.V., Japan, Category Revenue Share (2009) 47
10.2.5 Qiagen N.V., Other Asia-Pacific, Category Revenue Share (2009) 49
10.3 Qiagen N.V., Europe, Category Revenue Share (2009) 51
10.3.1 Qiagen N.V., France, Category Revenue Share (2009) 53
10.3.2 Qiagen N.V., Germany, Category Revenue Share (2009) 55
10.3.3 Qiagen N.V., Italy, Category Revenue Share (2009) 57
10.3.4 Qiagen N.V., Spain, Category Revenue Share (2009) 59
10.3.5 Qiagen N.V., United Kingdom, Category Revenue Share (2009) 61
10.3.6 Qiagen N.V., Other Europe, Category Revenue Share (2009) 63
10.4 Qiagen N.V., Middle East and Africa, Category Revenue Share (2009) 65
10.5 Qiagen N.V., North America, Category Revenue Share (2009) 67
10.5.1 Qiagen N.V., Canada, Category Revenue Share (2009) 69
10.5.2 Qiagen N.V., United States, Category Revenue Share (2009) 71
10.6 Qiagen N.V., South and Central America, Category Revenue Share (2009) 73
10.6.1 Qiagen N.V., Brazil, Category Revenue Share (2009) 75
10.6.2 Qiagen N.V., Other South and Central America, Category Revenue Share (2009) 77
11 Key Employees 79
12 Key Employee Biographies 80
13 Company Statement 81
14 Locations And Subsidiaries 82
14.1 Head Office 82
14.2 Other Locations & Subsidiaries 82
15 Financial Deals Landscape 84
15.1 Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010 84
16 Qiagen N.V. Detailed Deal Summary 86
16.1 Asset Purchase 86
16.1.1 QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business 86
16.1.2 QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology 87
16.2 Private Equity 88
16.2.1 QIAGEN Sells Synthetic DNA Business Unit 88
16.3 Partnerships 89
16.3.1 QIAGEN Enters Into An Agreement With Genome Diagnostics 89
16.3.2 QIAGEN Enters Into Distribution Agreement With Celera 90
16.3.3 QIAGEN Forms Joint Venture With Bio One Capital 91



16.3.4 Qiagen And Whatman Enter Into Distribution Agreement 92
16.3.5 QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement 93
16.3.6 QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics 94
16.3.7 Beckman Coulter Enters Into Co-Marketing Agreement With QIAGEN 95
16.3.8 Veridex Enters Into Co-Marketing Agreement With QIAGEN 96
16.3.9 Abbott Laboratories Signs An Agreement With Artus 97
16.3.10 Roche Enters Into Licensing Agreement With QIAGEN 98
16.3.11 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 99
16.3.12 QIAGEN Enters Into An Agreement With Roche And Idaho Technology 100
16.3.13 HandyLab Enters Into An Agreement With Qiagen 101
16.3.14 QIAGEN Extends Its Agreement With Epigenomics 102
16.4 Equity Offering 103
16.4.1 QIAGEN Completes Private Placement Of Its Common Stock For $640 Million 103
16.4.2 QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million 104
16.4.3 QIAGEN Completes Private Placement Of Notes Due 2024 For $150 Milion 105
16.5 Acquisition 106
16.5.1 QIAGEN Completes Acquisition Of ESE 106
16.5.2 QIAGEN Completes Acquisition Of SABiosciences 107
16.5.3 QIAGEN Completes Acquisition Of DxS 108
16.5.4 QIAGEN Completes Acquisition Of Explera 110
16.5.5 QIAGEN Acquires Corbett Life Science 111
16.5.6 QIAGEN Acquires Digene 112
16.5.7 QIAGEN Acquires eGene 114
16.5.8 QIAGEN Acquires Genaco Biomedical Products 115
16.5.9 QIAGEN Acquires Shenzhen PG Biotech 116
16.5.10 QIAGEN Acquires Tianwei 117
16.5.11 QIAGEN Acquires QIAGEN Hamburg 118
16.5.12 QIAGEN Acquires Artus 119
17 Recent Developments 120
17.1 Strategy And Business Planning 120
17.1.1 Sep 08, 2009: Qiagen Inaugurates New Asia Headquarters In Shanghai 120
17.1.2 Jun 16, 2009: Qiagen, Linkmed Sign Agreement To Transfer Distribution Rights 120
17.1.3 Feb 22, 2008: Qiagen Opens New Service Solutions Center In Singapore 121
17.2 Financial Announcements 121
17.2.1 Aug 09, 2010: Qiagen Reports Net Income Of $38.52 Million In Q2 2010 121
17.2.2 May 03, 2010: Qiagen Reports Net Income Of $33 Million In Q1 2010 123
17.2.3 Feb 08, 2010: Qiagen Reports Net Income Of $137.7 Million In 2009 124
17.2.4 Nov 09, 2009: Qiagen Reports Net Income Of $37.7 Million In Q3 2009 126
17.2.5 Aug 10, 2009: Qiagen Reports Net Income Of $30.9 Million In Q2 2009 127
17.2.6 May 04, 2009: Qiagen Posts Profit Of $24.6 Million In Q1 2009 129
17.2.7 Feb 09, 2009: Qiagen Reports Preliminary 2008 Results 130
17.2.8 Nov 10, 2008: Qiagen Reports 3Q 2008 Results 132
17.2.9 Aug 04, 2008: Qiagen Reports 2Q 2008 Results 133
17.2.10 May 05, 2008: Qiagen Reports Q1 2008 Results 134
17.2.11 Feb 11, 2008: Qiagen Reports Q4 2007 Results 136
17.3 Research And Development 137
17.3.1 Jan 12, 2009: QIAGEN led-Consortium Launches Project To Improve In-Vitro Diagnostics 137
17.3.2 Dec 03, 2007: QIAGEN, Bio*One Establish Dx Assays 138
17.4 Corporate Communications 139
17.4.1 Dec 14, 2009: Qiagen Added To NASDAQ-100 Index 139



17.4.2 Jan 26, 2009: QIAGEN Appoints New President For QIAGEN Japan 139
17.4.3 Jan 19, 2009: QIAGEN Appoints New Head, Global Regulatory Affairs 139
17.4.4 May 13, 2008: Qiagen Appoints VP, Molecular Diagnostic Sales For EMEAA 140
17.5 Legal and Regulatory 140
17.5.1 Apr 01, 2009: Qiagen Announces CAFC Rejects Third Wave 140
17.5.2 Jan 22, 2009: QIAGEN And Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents 141
17.6 Product News 142
17.6.1 Sep 01, 2010: QIAGEN Launches QIAsymphony RGQ System For Molecular Diagnostics 142
17.6.2 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control 142
17.6.3 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test 143
17.6.4 Jan 25, 2010: Qiagen Introduces QIAsymphony AS 144
17.6.5 Jan 18, 2010: Study Finds QIAGEN's Digene HPV Test Effective In Preventing Invasive Cervical Cancer 144
17.6.6 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit 145
17.6.7 Jun 03, 2009: QIAGEN's Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis 146
17.6.8 Apr 28, 2009: QIAGEN Provides Screening Tests For Swine Flu Virus 147
17.6.9 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test
Compared To Other Methods Including Pap 148
17.6.10 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women 149
17.6.11 Nov 10, 2008: QIAGEN Introduces CE-marked Molecular Assay For The Cancer Biomarker K-ras 149
17.6.12 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay In The EU To Detect Genetic Variation Causing Adverse Reactions In AIDS
Patients 150
17.6.13 Feb 14, 2008: QIAGEN And Center For Molecular Medicine Create Research Collaboration For Molecular Diagnostic Markers
For Breast Cancer, Other Women's Health Issues 150
17.6.14 May 11, 2007: Digene Research At Clinical Virology Symposium Shows Strides In Multiplex Genotyping Technology
Development 151
17.6.15 Apr 19, 2007: Digene Announces Exclusive Marketing and Distribution Agreement with Asuragen, Inc. for Signature Cystic
Fibrosis Screening Products. 151
17.7 Product Approvals 151
17.7.1 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test 151
17.7.2 Jun 03, 2009: QIAGEN's Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis 152
17.8 Clinical Trials 153
17.8.1 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control 153
17.8.2 Jan 18, 2010: Study Finds QIAGEN's Digene HPV Test Effective In Preventing Invasive Cervical Cancer 154
17.8.3 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test
Compared To Other Methods Including Pap 155
17.9 Other Significant Developments 156
17.9.1 Mar 08, 2010: QIAGEN Extends Support Of Cervical Cancer Screening Program For Underprivileged Chinese Women 156
17.9.2 May 28, 2009: Qiagen Awards Development Contract To Plexus 156
17.9.3 May 28, 2009: Qiagen To Supply Molecular Screening Solutions To Increase Safety Of Blood Donations In Brazil 157
17.9.4 Sep 22, 2008: Osmetech Signs Agreement With Qiagen For QIAplex-Based Respiratory Viral Molecular Test 157
17.9.5 Sep 18, 2008: Qiagen CEO To Present At UBS Conference 158
18 Appendix 159
18.1 Research Methodology 160
18.2 Secondary Research 160
18.3 Primary Research 161
18.4 Models 161
18.5 Forecasts 161
18.6 Expert Panels 161
18.7 GlobalData Consulting 162
18.8 Currency Conversion 163



18.9 Contact Us 164
18.10 Disclaimer 164

1.1 List of Tables
Table 1: Qiagen N.V., Key Facts, 2009 15
Table 2: Qiagen N.V., SWOT Analysis, 2009 23
Table 3: In Vitro Diagnostics, Global, Company Share by Revenue ($m), 2009 30
Table 4: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%), 2009 31
Table 5: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%), 2009 32
Table 6: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%), 2009 33
Table 7: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%), 2009 34
Table 8: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%), 2009 35
Table 9: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%), 2009 36
Table 10: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%) by Category, 2009 38
Table 11: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2009 40
Table 12: Qiagen N.V., In Vitro Diagnostics, Australia, Revenue ($m) and Market Share (%) by Category, 2009 42
Table 13: Qiagen N.V., In Vitro Diagnostics, China, Revenue ($m) and Market Share (%) by Category, 2009 44
Table 14: Qiagen N.V., In Vitro Diagnostics, India, Revenue ($m) and Market Share (%) by Category, 2009 46
Table 15: Qiagen N.V., In Vitro Diagnostics, Japan, Revenue ($m) and Market Share (%) by Category, 2009 48
Table 16: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2009 50
Table 17: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%) by Category, 2009 52
Table 18: Qiagen N.V., In Vitro Diagnostics, France, Revenue ($m) and Market Share (%) by Category, 2009 54
Table 19: Qiagen N.V., In Vitro Diagnostics, Germany, Revenue ($m) and Market Share (%) by Category, 2009 56
Table 20: Qiagen N.V., In Vitro Diagnostics, Italy, Revenue ($m) and Market Share (%) by Category, 2009 58
Table 21: Qiagen N.V., In Vitro Diagnostics, Spain, Revenue ($m) and Market Share (%) by Category, 2009 60
Table 22: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Revenue ($m) and Market Share (%) by Category, 2009 62
Table 23: Qiagen N.V., In Vitro Diagnostics, Other Europe, Revenue ($m) and Market Share (%) by Category, 2009 64
Table 24: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%) by Category, 2009 66
Table 25: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%) by Category, 2009 68
Table 26: Qiagen N.V., In Vitro Diagnostics, Canada, Revenue ($m) and Market Share (%) by Category, 2009 70
Table 27: Qiagen N.V., In Vitro Diagnostics, United States, Revenue ($m) and Market Share (%) by Category, 2009 72
Table 28: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%) by Category, 2009
74
Table 29: Qiagen N.V., In Vitro Diagnostics, Brazil, Revenue ($m) and Market Share (%) by Category, 2009 76
Table 30: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Revenue ($m) and Market Share (%) by Category,
2009 78
Table 31: Qiagen N.V., Key Employees 79
Table 32: Qiagen N.V., Subsidiaries 82
Table 33: Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010 84
Table 34: Qiagen N.V., Deals Summary, 2005 to YTD 2010 85
Table 35: QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business 86
Table 36: QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology 87
Table 37: QIAGEN Sells Synthetic DNA Business Unit 88
Table 38: QIAGEN Enters Into An Agreement With Genome Diagnostics 89
Table 39: QIAGEN Enters Into Distribution Agreement With Celera 90
Table 40: QIAGEN Forms Joint Venture With Bio One Capital 91
Table 41: Qiagen And Whatman Enter Into Distribution Agreement 92
Table 42: QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement 93
Table 43: QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics 94



Table 44: Beckman Coulter Enters Into Co-Marketing Agreement With QIAGEN 95
Table 45: Veridex Enters Into Co-Marketing Agreement With QIAGEN 96
Table 46: Abbott Laboratories Signs An Agreement With Artus 97
Table 47: Roche Enters Into Licensing Agreement With QIAGEN 98
Table 48: QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 99
Table 49: QIAGEN Enters Into An Agreement With Roche And Idaho Technology 100
Table 50: HandyLab Enters Into An Agreement With Qiagen 101
Table 51: QIAGEN Extends Its Agreement With Epigenomics 102
Table 52: QIAGEN Completes Private Placement Of Its Common Stock For $640 Million 103
Table 53: QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million 104
Table 54: QIAGEN Completes Private Placement Of Notes Due 2024 For $150 Milion 105
Table 55: QIAGEN Completes Acquisition Of ESE 106
Table 56: QIAGEN Completes Acquisition Of SABiosciences 107
Table 57: QIAGEN Completes Acquisition Of DxS 108
Table 58: QIAGEN Completes Acquisition Of Explera 110
Table 59: QIAGEN Acquires Corbett Life Science 111
Table 60: QIAGEN Acquires Digene 112
Table 61: QIAGEN Acquires eGene 114
Table 62: QIAGEN Acquires Genaco Biomedical Products 115
Table 63: QIAGEN Acquires Shenzhen PG Biotech 116
Table 64: QIAGEN Acquires Tianwei 117
Table 65: QIAGEN Acquires QIAGEN Hamburg 118
Table 66: QIAGEN Acquires Artus 119
Table 67: USD to Local Currency, Average Exchange Rate 2009 163

1.2 List of Figures

Figure 1: In Vitro Diagnostics, Global, Company Share (%), 2009 29
Figure 2: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%), 2009 31
Figure 3: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%), 2009 32
Figure 4: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%), 2009 33
Figure 5: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Market Share (%), 2009 34
Figure 6: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%), 2009 35
Figure 7: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%), 2009 36
Figure 8: Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (%), 2009 37
Figure 9: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%) by Category, 2009 38
Figure 10: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Category Revenue Share (%), 2009 39
Figure 11: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%) by Category, 2009 40
Figure 12: Qiagen N.V., In Vitro Diagnostics, Australia, Category Revenue Share (%), 2009 41
Figure 13: Qiagen N.V., In Vitro Diagnostics, Australia, Market Share (%) by Category, 2009 42
Figure 14: Qiagen N.V., In Vitro Diagnostics, China, Category Revenue Share (%), 2009 43
Figure 15: Qiagen N.V., In Vitro Diagnostics, China, Market Share (%) by Category, 2009 44
Figure 16: Qiagen N.V., In Vitro Diagnostics, India, Category Revenue Share (%), 2009 45
Figure 17: Qiagen N.V., In Vitro Diagnostics, India, Market Share (%) by Category, 2009 46
Figure 18: Qiagen N.V., In Vitro Diagnostics, Japan, Category Revenue Share (%), 2009 47
Figure 19: Qiagen N.V., In Vitro Diagnostics, Japan, Market Share (%) by Category, 2009 48
Figure 20: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Category Revenue Share (%), 2009 49
Figure 21: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Market Share (%) by Category, 2009 50
Figure 22: Qiagen N.V., In Vitro Diagnostics, Europe, Category Revenue Share (%), 2009 51
Figure 23: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%) by Category, 2009 52



Figure 24: Qiagen N.V., In Vitro Diagnostics, France, Category Revenue Share (%), 2009 53
Figure 25: Qiagen N.V., In Vitro Diagnostics, France, Market Share (%) by Category, 2009 54
Figure 26: Qiagen N.V., In Vitro Diagnostics, Germany, Category Revenue Share (%), 2009 55
Figure 27: Qiagen N.V., In Vitro Diagnostics, Germany, Market Share (%) by Category, 2009 56
Figure 28: Qiagen N.V., In Vitro Diagnostics, Italy, Category Revenue Share (%), 2009 57
Figure 29: Qiagen N.V., In Vitro Diagnostics, Italy, Market Share (%) by Category, 2009 58
Figure 30: Qiagen N.V., In Vitro Diagnostics, Spain, Category Revenue Share (%), 2009 59
Figure 31: Qiagen N.V., In Vitro Diagnostics, Spain, Market Share (%) by Category, 2009 60
Figure 32: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Category Revenue Share (%), 2009 61
Figure 33: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Market Share (%) by Category, 2009 62
Figure 34: Qiagen N.V., In Vitro Diagnostics, Other Europe, Category Revenue Share (%), 2009 63
Figure 35: Qiagen N.V., In Vitro Diagnostics, Other Europe, Market Share (%) by Category, 2009 64
Figure 36: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Category Revenue Share (%), 2009 65
Figure 37: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Market Share (%) by Category, 2009 66
Figure 38: Qiagen N.V., In Vitro Diagnostics, North America, Category Revenue Share (%), 2009 67
Figure 39: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%) by Category, 2009 68
Figure 40: Qiagen N.V., In Vitro Diagnostics, Canada, Category Revenue Share (%), 2009 69
Figure 41: Qiagen N.V., In Vitro Diagnostics, Canada, Market Share (%) by Category, 2009 70
Figure 42: Qiagen N.V., In Vitro Diagnostics, United States, Category Revenue Share (%), 2009 71
Figure 43: Qiagen N.V., In Vitro Diagnostics, United States, Market Share (%) by Category, 2009 72
Figure 44: Qiagen N.V., In Vitro Diagnostics, South and Central America, Category Revenue Share (%), 2009 73
Figure 45: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%) by Category, 2009 74
Figure 46: Qiagen N.V., In Vitro Diagnostics, Brazil, Category Revenue Share (%), 2009 75
Figure 47: Qiagen N.V., In Vitro Diagnostics, Brazil, Market Share (%) by Category, 2009 76
Figure 48: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Category Revenue Share (%), 2009 77
Figure 49: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Market Share (%) by Category, 2009 78
Figure 50: Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010 84

Companies mentioned
Abbott Laboratories
Alere Inc
Beckman Coulter, Inc.
Becton, Dickinson and Company
Biomerieux Sa
Bio-Rad Laboratories, Inc.
DiaSorin S.p.A
F. Hoffmann-La Roche Ltd.
Fisher Scientific Corporation
Gen-Probe Incorporated
Hologic, Inc.
Life Technologies Corporation
Macherey-Nagel GmbH & Co.
Millipore Corporation
Olympus Medical Systems Corp.
Ortho-Clinical Diagnostics Inc.
Promega Corporation
Roche Diagnostics Limited
Siemens Healthcare
Sigma-Aldrich Corporation
Sysmex Corporation



Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 000.00 Quantity: _____

Site License--USD 2 000.00 Quantity: _____

Corporate License--USD 3 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________



Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Qiagen N.V. Market Share Analysis

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (18)

More from ReportLinker.com

More from ReportLinker.com (20)

Recently uploaded

Recently uploaded (20)

Qiagen N.V. Market Share Analysis